BridgeBio Pharma, Inc. (BBIO) stock
BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$78.01+1.21 (+1.58%)
Close on Nov 18, 2026Market cap $15.20BP/E –Yield –
BridgeBio Pharma shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
BridgeBio Pharma's shares outstanding was 196M at Sep 30, 2026. For fiscal 2025 it was 192M, up 2.9% from the year before. The highest annual figure on record is 192M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 192M | +2.9% |
| FY2024 | Dec 31, 2024 | 186M | +14.3% |
| FY2023 | Dec 31, 2023 | 163M | +10.4% |
| FY2022 | Dec 31, 2022 | 147M | +2.2% |
| FY2021 | Dec 31, 2021 | 144M | +22.3% |
| FY2020 | Dec 31, 2020 | 118M | +12.3% |
| FY2019 | Dec 31, 2019 | 105M | +70.2% |
| FY2018 | Dec 31, 2018 | 62M | +101.9% |
| FY2017 | Dec 31, 2017 | 31M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 196M | +2.2% |
| Q2 FY2026 | Jun 30, 2026 | 196M | +2.8% |
| Q1 FY2026 | Mar 31, 2026 | 195M | +2.4% |
| Q4 FY2025 | Dec 31, 2025 | 194M | +2.2% |
| Q3 FY2025 | Sep 30, 2025 | 192M | +1.8% |
| Q2 FY2025 | Jun 30, 2025 | 191M | +1.6% |
| Q1 FY2025 | Mar 31, 2025 | 190M | +6.4% |
| Q4 FY2024 | Dec 31, 2024 | 189M | +8.6% |
| Q3 FY2024 | Sep 30, 2024 | 189M | +15.4% |
| Q2 FY2024 | Jun 30, 2024 | 188M | +16.9% |
| Q1 FY2024 | Mar 31, 2024 | 179M | +17.1% |
| Q4 FY2023 | Dec 31, 2023 | 174M | +16.8% |
| Q3 FY2023 | Sep 30, 2023 | 163M | +10.4% |
| Q2 FY2023 | Jun 30, 2023 | 161M | +9.4% |
| Q1 FY2023 | Mar 31, 2023 | 153M | +4.6% |
| Q4 FY2022 | Dec 31, 2022 | 149M | +2.8% |
| Q3 FY2022 | Sep 30, 2022 | 148M | +0.9% |
| Q2 FY2022 | Jun 30, 2022 | 147M | -0.0% |
| Q1 FY2022 | Mar 31, 2022 | 146M | +5.2% |
| Q4 FY2021 | Dec 31, 2021 | 145M | +22.1% |
| Q3 FY2021 | Sep 30, 2021 | 147M | +24.1% |
| Q2 FY2021 | Jun 30, 2021 | 147M | +25.4% |
| Q1 FY2021 | Mar 31, 2021 | 139M | +17.7% |
| Q4 FY2020 | Dec 31, 2020 | 119M | +1.0% |
| Q3 FY2020 | Sep 30, 2020 | 118M | +0.9% |
| Q2 FY2020 | Jun 30, 2020 | 117M | +26.0% |
| Q1 FY2020 | Mar 31, 2020 | 118M | +27.6% |
| Q4 FY2019 | Dec 31, 2019 | 118M | +57.6% |
| Q3 FY2019 | Sep 30, 2019 | 117M | +92.1% |
| Q2 FY2019 | Jun 30, 2019 | 93M | – |
| Q1 FY2019 | Mar 31, 2019 | 92M | – |
| Q4 FY2018 | Dec 31, 2018 | 75M | – |
| Q3 FY2018 | Sep 30, 2018 | 61M | – |
See a number that looks wrong?